Healthy volunteers help test new Drug's safety
NCT ID NCT07134127
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 36 times
Summary
This early-phase study tested the safety and how the body processes a single dose of IBI3032 in 40 healthy adults. Participants were divided into groups, some receiving the drug and others a placebo, with some groups also checking if food affects the drug. The main goal was to monitor side effects and measure drug levels in the blood. No treatment benefit was expected; the study simply gathered safety information.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The Frist Affiliated Hospital of Anhui Medical University
Hefei, Anhui, 230000, China
Conditions
Explore the condition pages connected to this study.